Rhosyll Gabriel

Papers

2

Total Citations

346

H-Index

2

About

Rhosyll Gabriel is a leading urologic oncology researcher whose work centers on optimizing surgical outcomes for bladder cancer patients, particularly through the comparative effectiveness of robot-assisted versus open radical cystectomy. Gabriel’s most influential contribution is a landmark 2022 study published in *JAMA*, which demonstrated that robot-assisted radical cystectomy with intracorporeal urinary diversion does not significantly reduce 90-day morbidity or mortality compared to open surgery—a finding that has garnered over 320 citations and reshaped clinical debate around minimally invasive approaches. Building on this, Gabriel conducted a rigorous cost-effectiveness analysis in 2023, revealing that while robotic surgery offers comparable clinical outcomes, its higher procedural costs challenge its value from a payer perspective. This work provides crucial evidence for healthcare policy and surgical decision-making. Gabriel’s research is distinguished by its integration of clinical trial data with health economics, offering a balanced, data-driven perspective on surgical innovation. By directly addressing the trade-offs between recovery, cost, and survival, Gabriel has become a key voice in evidence-based urologic surgery, guiding both practitioners and policymakers toward more informed, patient-centered care.

Research Focus

Key Achievements

2
H-Index
2
Papers
346
Total Citations
173
Avg Citations/Paper
🏆 Most Cited Paper
Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer
320 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 70

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago